Bristol Myers (BMY) Gets FDA Approval for CAR T-Cell Therapy

Bristol Myers Squibb BMY announced that the FDA has approved its CD19-directed chimeric antigen receptor (CAR) T cell therapy, Breyanzi (lisocabtagene maraleucel; liso-cel).Bristol Myers Squibb BMY announced that the FDA has approved its CD19-directed chimeric antigen receptor (CAR) T cell therapy, Breyanzi (lisocabtagene maraleucel; liso-cel).Read MoreStocks,InvestingStocks Feed